Progenics Pharmaceuticals, Inc. (PGNX) Misses Q4 EPS by 3c; Founder Maddon to Retire
Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) reported Q4 EPS of ($0.32), $0.03 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $2.2 million versus the consensus estimate of $7.37 million.
The company also announced that company founder Paul J. Maddon, M.D., Ph.D. has retired as chief science officer of the company. He continues as a member and vice chair of the Progenics board of directors.
The company also announced that company founder Paul J. Maddon, M.D., Ph.D. has retired as chief science officer of the company. He continues as a member and vice chair of the Progenics board of directors.
For earnings history and earnings-related data on Progenics Pharmaceuticals, Inc. (PGNX) click here.